STOCK TITAN
  1. Home
  2. News
  3. VIGL

Vigil Neuroscience Inc - VIGL STOCK NEWS

IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
clinical trial
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
conferences
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
clinical trial
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
clinical trial
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
conferences
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
management
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
conferences
IMPACT
SENTIMENT
VIGL : Nasdaq
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
earnings
Stock VIGL logo
Vigil Neuroscience Inc
Nasdaq:VIGL

VIGL Stock Data

Research and Development in Biotechnology
Professional, Scientific, and Technical Services

About VIGL

vigil neuroscience is the world’s first microglia-focused therapeutics company. our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. we are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.